By targeting PDGFR, CSF1R, and c-KIT, seralutinib could lead to the reverse remodeling of pulmonary vascular disease in PAH, with a consequent improvement in clinically meaningful outcomes with a limited risk for adverse events. Here, CSF1R is linked to pulmonary arterial hypertension.